News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
19,466 Results
Type
Article (649)
Company Profile (10)
Press Release (18807)
Section
Business (9971)
Career Advice (12)
Deals (1238)
Drug Development (2012)
FDA (290)
Job Trends (381)
News (12728)
Policy (579)
Tag
Academia (74)
Accelerated approval (1)
Allergies (5)
Alliances (738)
ALS (3)
Alzheimer's disease (176)
Antibody-drug conjugate (ADC) (16)
Approvals (307)
Artificial intelligence (3)
Autoimmune disease (4)
Automation (1)
Bankruptcy (10)
Best Places to Work (362)
Biosimilars (4)
Biotechnology (5)
Bladder cancer (5)
Breast cancer (13)
Cancer (114)
Cardiovascular disease (10)
Career advice (12)
CAR-T (1)
CDC (3)
Cell therapy (4)
Cervical cancer (1)
Clinical research (1822)
Collaboration (8)
Compensation (14)
COVID-19 (40)
CRISPR (3)
C-suite (4)
Cystic fibrosis (5)
Data (269)
Depression (4)
Dermatology (5)
Diabetes (19)
Diagnostics (486)
Digital health (1)
Drug discovery (3)
Duchenne muscular dystrophy (5)
Earnings (9565)
Editorial (2)
Events (1670)
Executive appointments (1)
FDA (460)
Friedreich's ataxia (1)
Frontotemporal dementia (2)
Funding (14)
Gene editing (5)
Gene therapy (7)
GLP-1 (38)
Government (49)
Guidances (115)
Healthcare (661)
Huntington's disease (1)
IgA nephropathy (4)
Immunology and inflammation (8)
Indications (5)
Infectious disease (47)
Inflammatory bowel disease (3)
Influenza (1)
Intellectual property (4)
IPO (966)
Job creations (43)
Job search strategy (12)
JPM (2)
Layoffs (32)
Legal (84)
Liver cancer (3)
Lung cancer (27)
Lymphoma (14)
Manufacturing (8)
MASH (9)
Medical device (1219)
Medtech (1223)
Mergers & acquisitions (276)
Metabolic disorders (47)
mRNA (4)
Multiple sclerosis (5)
Neurodegenerative disease (23)
Neuropsychiatric disorders (2)
Neuroscience (217)
NextGen: Class of 2026 (150)
Non-profit (42)
Obesity (13)
Opinion (15)
Ovarian cancer (1)
Pancreatic cancer (4)
Parkinson's disease (12)
Patents (8)
Patient recruitment (8)
Peanut (3)
People (676)
Pharmaceutical (4)
Phase 1 (449)
Phase 2 (794)
Phase 3 (719)
Pipeline (614)
Policy (4)
Postmarket research (78)
Preclinical (177)
Press Release (1)
Prostate cancer (6)
Radiopharmaceuticals (6)
Rare diseases (21)
Real estate (79)
Regulatory (527)
Reports (1)
Research institute (65)
Rett syndrome (1)
RSV (5)
Schizophrenia (4)
Sickle cell disease (2)
Spinal muscular atrophy (4)
Startups (45)
Stomach cancer (1)
Tariffs (1)
Vaccines (26)
Venture capital (1)
Weight loss (13)
Women's health (3)
Date
Last 7 days (17)
Last 30 days (112)
Last 365 days (1177)
2026 (292)
2025 (1185)
2024 (1259)
2023 (1478)
2022 (1618)
2021 (1672)
2020 (1451)
2019 (1058)
2018 (783)
2017 (3984)
2016 (336)
2015 (523)
2014 (361)
2013 (189)
2012 (221)
2011 (305)
2010 (367)
Location
Africa (11)
Alabama (3)
Arizona (10)
Asia (1097)
Australia (144)
California (424)
Canada (98)
China (36)
Colorado (23)
Connecticut (26)
Delaware (19)
Europe (2623)
Florida (70)
Georgia (13)
Idaho (1)
Illinois (41)
India (1)
Indiana (23)
Japan (11)
Kansas (4)
Kentucky (2)
Louisiana (5)
Maine (4)
Maryland (60)
Massachusetts (334)
Michigan (11)
Minnesota (26)
Missouri (6)
Nevada (2)
New Hampshire (3)
New Jersey (125)
New York (174)
North Carolina (51)
Northern California (214)
Ohio (8)
Oregon (1)
Pennsylvania (106)
South America (29)
South Carolina (2)
Southern California (179)
Tennessee (2)
Texas (55)
United States (1672)
Utah (27)
Virginia (5)
Washington State (44)
Wisconsin (3)
19,466 Results for "181".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Roche’s Elecsys® pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer’s-related amyloid pathology
October 14, 2025
·
6 min read
IPO
Eikon, Veradermics, Announce IPO Targets as Cautious Optimism Propels Biotech Market
Cancer-focused Eikon Therapeutics is seeking $273.5 million in its bid to trade on the Nasdaq, while hair growth specialist Veradermics is looking for $181.1 million in its foray onto the New York Stock Exchange.
January 29, 2026
·
3 min read
·
Tristan Manalac
Drug Development
Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced encouraging data from its Phase 1 DRAGON proof-of-concept trial of SRK-181, a selective inhibitor of latent TGFβ1 activation, in combination with pembrolizumab in patients with advanced solid tumors.
June 3, 2024
·
11 min read
Drug Development
Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Scholar Rock (NASDAQ: SRRK) today announced it will present new data from its Phase 1 DRAGON proof-of-concept trial of SRK-181 in combination with pembrolizumab in patients with advanced solid tumors in an oral presentation during the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31 – June 4 in Chicago.
May 28, 2024
·
9 min read
ADCs
Don’t Call It a Crossover, but Alentis Raises $181M Series D for ADC Work
CEO Roberto Iacone admitted in an interview that the market remains tough, even for a biotech in the red-hot ADC world. But Alentis is targeting an IPO as early as 2025.
November 12, 2024
·
2 min read
·
Annalee Armstrong
BioCapital
NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease
NextCure, Inc. (Nasdaq: NXTC) today announced the presentation of preclinical data relating to NC181, a novel humanized antibody targeting ApoE4, for the treatment of Alzheimer’s disease (AD), at the 2nd Annual Neurodegeneration Targets, Drug Discovery for Progressive Central Nervous System Disorders conference.
September 26, 2023
·
4 min read
BioCapital
Initial Clinical Data of First Pediatric CLN2 Patient Dosed with RGX-181 Presented at SSIEM Annual Symposium
REGENXBIO Inc. announced that initial interim data from a first-in-human single-patient, investigator-initiated trial of RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 disease, a form of Batten disease, were presented at the Society for the Study of Inborn Errors of Metabolism Annual Symposium in Jerusalem.
August 30, 2023
·
8 min read
Press Releases
Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors
November 12, 2024
·
6 min read
Drug Development
Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability
Scholar Rock (NASDAQ: SRRK) today announced new data from its Phase 1 DRAGON proof-of-concept trial of SRK-181, a selective inhibitor of latent TGFβ1 activation being developed with the aim of overcoming resistance to checkpoint inhibitor therapy in patients with advanced cancer.
November 3, 2023
·
12 min read
Press Releases
Lyme Disease Market Size to Reach USD 1,181.7 Million by 2034, Impelled by Immunomodulatory Therapies
August 1, 2024
·
10 min read
1 of 1,947
Next